----- SPECIAL EDITION -----
European Association for the Study of Diabetes (EASD) 2023
PICTURE CREDIT: EASD – European Association for the Study of Diabetes
The 59th Annual Meeting of the European Association for the Study of Diabetes (EASD) took place this week in Hamburg, Germany, with thousands of healthcare professionals attending the annual event both in-person and online.
The conference programme delivered a range of daily sessions, with a mix of plenaries, symposiums and workshops.
A variety of speakers from around the world presented the latest developments in diabetes treatment and discussed the most pressing and controversial areas relating to management.
For pregnant women with type 1 diabetes, a technology giving insulin doses, as informed by a smartphone algorithm, helps them better manage their blood sugars compared with traditional insulin pumps or multiple daily injections, latest research has reported.
This new randomised trial was published in The New England Journal of Medicine and has been presented at the European Association for the Study of Diabetes (EASD) meeting in Hamburg.
A new meta-analysis combining 22 studies shows that tirzepatide is superior to semaglutide for both blood sugar control and weight loss, research reveals.
The study, which was led by Dr Thomas Karagiannis from Aristotle University of Thessaloniki, has been presented at this year’s annual meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany.
Tirzepatide is as effective at treating early-onset type 2 diabetes as it is at treating type 2 diabetes diagnosed later in life, new research presented at EASD has found.
Tirzepatide belongs to a new class of drugs that mimic the effect of two hormones involved in blood sugar control and appetite suppression, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
New research presented at this year’s EASD meeting shows that semaglutide significantly improves blood sugar control and weight loss in adults with type 2 diabetes for up to three years. To read more, click here.
Over the past five years there has been a sharp trend towards the use of semaglutide in both oral and injectable form to treat people with type 2 diabetes, new research shows. To read more, click here.
Six adults with type 1 diabetes treated with stem cell-derived islet cells have shown improved blood sugar control, with three participants achieving insulin independence.
This is according to new research presented at this year’s annual meeting of The European Association for the Study of Diabetes (EASD) in Hamburg.
The use of the FreeStyle Libre continuous glucose monitoring system is associated with significant reductions in HbA1c, new data from has revealed.
Abbott has also announced that the FreeStyle Libre continuous glucose monitoring (CGM) system reduces the number of hospital admissions for people living with type 2 diabetes on both multiple daily injection (MDI) and once-daily (basal) insulin therapy.
A global leader in real-time continuous glucose monitoring (CGM) for people with diabetes has announced new clinical study outcomes that further demonstrate the benefits of CGM use.
At the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD) held in Hamburg, Germany, Dexcom has offered more details about its expanding portfolio of automated insulin delivery offerings.
The possibility of universal screening for type 1 diabetes was the theme of a session at this year’s EASD annual meeting in Hamburg, Germany.
The talk was given by Dr Emily K. Sims, Associate Professor of Pediatrics, Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN, USA.
Healthcare professionals are being invited to attend a webinar to learn more about Trend Diabetes’ updated Injection Technique Matters guideline.
The online event has been designed to showcase the new national safety document entitled ‘For Healthcare Professionals: CORRECT INJECTION TECHNIQUE IN DIABETES CARE. BEST PRACTICE GUIDELINE. 3rd edition’.
New research presented at EASD has identified a range of characteristics associated with a higher risk of sudden cardiac arrest in individuals with type 2 diabetes. To read more, click here.
New research reveals an increase in several common conditions in the years leading up to, and immediately prior to, type 2 diabetes diagnosis. To read more, click here.
Thousands of people with early onset type 2 diabetes will benefit from more targeted care, thanks to an initiative from the NHS. To read more, click here.
NHS England, Diabetes UK and the JDRF have launched an interactive peer support tool for people living with type 1 diabetes. To read more, click here.
A campaign has been launched urging everyone with diabetes to carry a card featuring potentially life-saving advice.
The HypoCard, which can fit inside a wallet or purse, provides vital tips on what to do if the card carrier experiences a hypo (hypoglycaemia) – a life-threatening condition triggered when blood sugar levels fall under 4mmol/L. Too much insulin or too little food can spark a hypo.
An online platform that allows healthcare professionals to securely connect with their patients’ blood glucose readings will be the focus of a webinar. To read more, click here.
New research presented at EASD has linked infant formula and the early introduction of fizzy drinks with higher levels of body fat later in childhood. To read more, click here.
Hypoglycaemia is more than twice as common among adults with diabetes who struggle to afford food, research has found. To read more, click here.
Exposure to natural light could help treat and prevent type 2 diabetes, new research has revealed. To read more, click here.
A clinician and educator has won a prestigious accolade for her “profound influence on healthcare education” at this year’s University Hospitals of Leicester’s (UHL) Recognition Awards. To read more, click here.
A cardio-diabetic outpatient service at Lincolnshire Heart Centre is helping reduce recurring heart attacks in people with diabetes by providing a holistic one-stop approach to patient care. To read more, click here.
Bringing you the latest jobs from around the country within the field of diabetes.
Lead Advanced Clinical Pharmacist Diabetes and Endocrinology – Sheffield Teaching Hospitals NHS Foundation Trust
Diabetes Specialist Dietitian – Cambridgeshire and Peterborough NHS Foundation Trust
Diabetes Midwife – Hampshire Hospitals NHS Foundation Trust
Diabetes Nurse – Midlands Partnership NHS Foundation Trust
Join the expanding diabetes community on Twitter and follow us for the latest diabetes news updates at @DiabetesTimes.
We are now on YouTube where you will find interviews with leading figures within the field of diabetes. Click here to visit our page.
